Skip to main content
Figure 7 | Fibrogenesis & Tissue Repair

Figure 7

From: HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation

Figure 7

HDAC inhibition diminished α-SMA activation in cardiac fibroblast. CD90+ cells were isolated from atrial explants after 21 days in culture. (A) Cells were treated with Mocetinostat for 7 days. Relative gene expressions were measured with real-time PCR. Mocetinostat treatment elevated E-cadherin levels, while reducing α-SMA, MMP2, and Collagen-III. (B) CD90 cells isolated from ventricles were treated with Mocetinostat for 7 days. Levels of α-SMA, MMP2, and Collagen-III were reduced with Mocetinostat treatment, while E-cadherin expression was unaltered. (C) Western blot analysis of α-SMA in Mocetinostat treated atrial and ventricular CD90+ cells. Error bars indicate S.E. (n = 4). P <0.05. MMP2, Matrix metalloproteinase-2; Moce, Mocetinostat; SMA, α-Smooth muscle actin.

Back to article page